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English summary 
 
Breast cancer is the most common cancer in women. Mortality have 
declining in the recent decades due to advances in treatment and 
diagnosis.  
Ki67 is a nuclear protein expressed in proliferating cells, where it 
acts as a surfactant that prevents chromosomal collapse during 
mitosis. This unique cyclic expression pattern enables identification 
of proliferating cells in histological slides by immunohistochemical 
(IHC) staining for Ki67. The Ki67 Proliferation Index (PI) (fraction 
of Ki67 positive cells) is an important prognostic marker in breast 
carcinomas, where increased Ki67 PI is associated with higher 
mortality and risk of relapse. Ki67 PI have also been suggested as 
surrogate marker to distinguish between two molecular subtypes of 
breast carcinomas: Luminal A and B. 
However, correct and reproducible assessment of Ki67 PI is 
challenging due to significant variance in IHC staining procedures 
and Ki67 interpretation practices among pathology laboratories. The 
general aim of the studies included in this thesis was to address 
some of these standardization issues.  
In study 1, we examined the interobserver variation of Ki67 PI 
scoring in a large cohort (n=199) of pathology laboratories that 
examined the same fifteen Ki67 IHC stained breast carcinomas. 
Overall, there was good agreement between the participants, but 
when applying a cutoff of 20% only modest kappa values were 
observed. Participants that estimated Ki67 PI in hotspots reported 
higher values than participants that scored an overall average. 
Similarly, participants who considered weak Ki-67 nuclear staining 
positive obtained higher Ki-67 PIs than those who did not. A 
computer algorithm (Virtual Double Staining (VDS)) obtained Ki-67 
values similar to the mean value of participants. 
In study 2, we compared a Digital Image Analysis (DIA) algorithm 
VDS that fuses two parallel sections (one for tumour identification 
and one for Ki67 PI estimation) with stereologically obtained Ki67 
PI by a human observer. 140 breast carcinomas were examined, 
and we found almost perfect correlation between the two methods 
(ICC > 0.97). 
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In study 3, we examined the impact of selection of primary antibody 
clones, antibody formats and stainer platforms on Ki67 PI obtained 
by VDS in breast carcinomas. Significant differences in Ki67 PIs 
were observed between the different antibody, format and platform 
combinations. Similarly, variations in proportion of carcinomas with 
high level Ki67 (above 20%) were seen indicating that IHC 
methodology can be an important source of variation. 
In study 4, we examined the potential of cell lines as supplementary 
Ki67 IHC performance controls. Ki67 IHC was assessed as H-scores 
by two different DIA programs. We found low day-to-day variation 
in Ki67 IHC H-scores in normal slides. Suboptimally stained slides 
could be identified on the basis of lower H-scores.  
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Dansk resumé 
 
Brystkræft er den mest almindelige kræftform blandt kvinder. 
Dødeligheden er faldet i de seneste årtier på grund af fremskridt 
inden for diagnosticering og behandling. 
Ki67 er et kerneprotein, der udtrykkes i delende celler. Her fungerer 
det som surfaktant, der forhindrer kromosomalt kollaps under 
mitosen. Dette unikke cykliske udtryksmønster muliggør 
identifikation af prolifererende celler i immunohistokemisk (IHC) 
Ki67-farvede histologiske snit. Ki67 Proliferation Index (PI) 
(fraktionen af Ki67-positive celler) er en vigtig prognostisk markør 
i mammakarcinomer, hvor øget Ki67 PI er forbundet med højere 
dødelighed og risiko for tilbagefald. Ki67 PI har desuden været 
foreslået som surrogatmarkør til at skelne mellem to molekylære 
subtyper af mammakarcinomer: Luminal A og B. 
Korrekt og reproducerbar vurdering af Ki67 PI er imidlertid 
udfordrende på grund af betydelig variation i IHC-procedurer og 
Ki67-fortolkningspraksis blandt patologilaboratorier grundet 
manglende standardisering. Det overordnede formål med studierne 
inkluderet i denne afhandling var at undersøge nogle af disse 
standardiseringsudfordringer. 
I studie 1 undersøgte vi interobservatør variationen af Ki67 PI i en 
stor kohorte (n=199) af patologilaboratorier, der undersøgte de 
samme femten digitaliserede Ki67 IHC-farvede mammakarcinomer. 
Generelt var der en god overensstemmelse mellem deltagernes 
resultater, men ved anvendelse af et cutoff på 20% observerede vi 
kun beskedne kappa-værdier. Deltagere, der estimerede Ki67 PI i 
hotspots, rapporterede højere værdier end deltagere, der scorede 
et samlet gennemsnit. Tilsvarende opnåede deltagere, der 
betragtede svage Ki67 kernefarvninger som positive, højere Ki-67-
PI end dem, der opfattede dem som negative. Computeralgoritmen 
Virtual Double Staining (VDS) opnåede Ki-67 PI svarende til 
deltagernes gennemsnit. 
I studie 2 sammenlignede vi en Digital Image Analyse (DIA) 
algoritme, VDS, der fusionerer to parallelle snit (et til 
tumoridentifikation og et til Ki67 PI-estimering) med stereologiske 
estimater af Ki67 PI fra en menneskelig observatør. 140 
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mammakarcinomer blev undersøgt, og vi fandt en næsten perfekt 
overensstemmelse mellem de to metoder (ICC > 0,97). 
I studie 3 undersøgte vi effekten af forskellige primære 
antistofkloner, antistof-formater og farveplatforme på Ki67 PI i 
mammakarcinomer, der blev estimeret ved hjælp af algoritmen 
VDS. Vi observerede signifikante forskelle blandt de forskellige 
antistofkloner, formater og platformkombinationer. Tilsvarende 
observerede vi betydelige variationer i andelen af karcinomer med 
højt niveau af Ki67 PI (over 20%), hvilket indikerer, at IHC-
metodologien er en vigtig kilde til variation. 
Endeligt undersøgte vi i studie 4 potentialet for cellelinjer som Ki67 
IHC performancekontroller. Ki67 IHC blev vurderet ved hjælp af en 
H-score beregnet af to forskellige DIA-programmer. Vi fandt lav 
dag-til-dag variation i Ki67 IHC H-score. Suboptimalt farvede snit 
kunne desuden identificeres på basis af lavere H-score. 
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1 Scientific papers 
This PhD thesis is based on four independent scientific papers and 
referred to in thesis using Arabic numbers (1-4) in the order listed 
below. 
 
1.  
Røge R, Nielsen S, Riber-Hansen R, Vyberg M. Ki67 proliferation 
index in breast cancer as a function of assessment method. A 
NordiQC experience. Appl Immunohistochem Mol Morphol. 
2020;10.1097/PAI.0000000000000846. 
doi:10.1097/PAI.0000000000000846. Online ahead of print. 
 
2. 
Røge R, Riber-Hansen R, Nielsen S, Vyberg M. Proliferation 
assessment in breast carcinomas using digital image analysis based 
on virtual Ki67/cytokeratin double staining. Breast Cancer Res 
Treat. 2016 Jul;158(1):11-19. doi: 10.1007/s10549-016-3852-6. 
 
3. 
Røge R, Nielsen S, Riber-Hansen R, Vyberg M. Impact of Primary 
Antibody Clone, Format, and Stainer Platform on Ki67 Proliferation 
Indices in Breast Carcinomas. Appl Immunohistochem Mol Morphol. 
2019 Nov/Dec;27(10):732-739. 
 
4. 
Røge R, Nielsen S, Riber-Hansen R, Vyberg M. Potential of Cell Lines 
Assessed by Image Analysis Used as Performance Controls of Ki67 
Immunostained. Appl Immunohistochem Mol Morphol. 2020 Mar 9.  
doi: 10.1097/PAI.0000000000000845. Online ahead of print. 
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2 Background 
 
2.1 Ki67 
 
2.1.1 Gene and structure 
 
Ki67 is a nuclear protein encoded by the MKI67 gene located on the 
long arm of chromosome 10 [1]. The name originated from a 
laboratory in Kiel that produced the prototype antibody (Ab) in well 
67 of a 96-well plate using a HL-60 (Hodgkin lymphoma) cell line 
[2]. In humans, it exists in two isoforms with the molecular weights 
of 320 kDa and 359 kDa [3]. 
 
Figure 2.1. Ultrastructure of Ki67 protein. (courtesy of Emw - released 
under creative commons 3.0) 
The MKI67 gene is found in all species of vertebrates [4]. It consist 
of several different regions [5]: N-terminal forkhead associated 
(FHA) domain, phosphatase binding (PB) domain, tandem repeats 
containing domain and a leucine and arginine-rich (LR) C-terminal. 
The FHA is a phosphopeptide recognition domain, which is found in 
many regulatory proteins that generally are involved in assembly of 
protein complexes [6,7]. The phosphatase binding domain interacts 
with certain isoforms of protein phosphatase 1, which, besides many 
other functions, protect the centromeric cohesion from 
phosphorylation during mitosis [8,9]. The central region of Ki67 
consists of 16 tandem repeats that are phosphorylated during 
mitosis by cyclin dependent kinase 1 [5,10]. This makes the protein 
highly positively electrostatic charged. The LR domain contains 
many leucine and arginine amino acids that have the ability to bind 
to DNA [11]. This domain also binds to heterochromatin 1 that are 
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involved in transcription, DNA repair and nuclear architecture 
[12,13]. 
 
Figure 2.2. Ki67 gene structure. (FHA: Fork head associated domain, PB: 
phosphatase binding domain, LR: Leucine/arginine rich domain) 
2.1.2 Function and expression pattern 
 
The function of Ki67 eluded the scientific community for many 
years. From the localization of the protein and the cyclic 
phosphorylation it was clear that it was related to cell division. 
However, the exact nature behind especially the tandem repeats 
remained unclear until a landmark publication in 2016, where 
Cuylen et al. showed that Ki67 acted as a chromosomal surfactant 
preventing chromosomes from collapsing after disassembly [14], 
which is crucial for chromosome motility during cell division. The 
structural explanation behind this is the pattern of Ki67 interaction 
with DNA. The positively charged repeated tandems within the 
central part of Ki67 cover the surface of the chromosomes and will, 
due to the positive charge, repel each other. During mitosis Ki67 
comprise the majority of this perichromosomal layer formed 
together with other proteins [15]. The LR region binds to DNA, while 
the FHA and PB regions interact with regulatory proteins in the 
nucleoplasm. 
Recently, it has also been shown that Ki67 play a role in regulating 
cell proliferation during interphase [16]. 
 
Sobecki et al. showed that Ki67 protein expression increases 
throughout the G2-phase and peaks in M-phase of the cell cycle [17] 
in both normal and neoplastic cells. This was also reflected in the 
mRNA expression, which peaked in G2. During the G1-phase Ki67 
is degraded although some Ki67 remain until cells enter full 
quiescence. During the interphase, Ki67 is located to nucleoli 
[16,18]. This pattern is also observed in IHC staining slides where 
some cells (most likely cells in M- or early G-phase) are completely 
stained, while other cells only have a dot-like reaction pattern due 
to accumulation in the nucleoli. 
 
2.2 Immunohistochemistry 
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The discovery of Ki67, based on the anti-Ki67 (Ki-67) Ab, was a 
landmark in the immunohistochemical (IHC) field. It was now 
possible to distinguish between proliferating and non-proliferating 
cells. A number of studies correlated proliferation and outcome and 
found prognostic values of Ki67 [19,20]. As an example, Hall et al. 
found worse survival in patients with a low-grade Hodgkin 
lymphoma with a high percentage of Ki67 positive cells [19]. 
Unfortunately, the prototypic Ab was limited to fresh and frozen 
tissue only. 
 
Since then many new antibodies (both polyclonal and monoclonal) 
have been developed, which can also be used on formalin-fixed 
tissue. The most commonly used Ab is Mib1 that was introduced 
alongside Mib2 and Mib3 by Cattoretti et al. [21]. The IHC staining 
protocol did now include a Heat-Induced-Epitope-Retrieval (HIER) 
step, where the tissues were boiled in low pH buffers [22]. 
According to NordiQC that examined the IHC staining quality of Ki67 
in 2016, 54% (220/409) of the participants used this clone for 
detection of Ki67 [23]. Other commonly used commercially 
available clones are MM1 (Leica/Novocastra, UK), SP6 (rabbit 
monoclonal, available from many vendors) and 30.9 (rabbit 
monoclonal, Roche/Ventana, Tucson, US). The vast majority of 
staining protocols included epitope retrieval. None of the 
participants used the prototypic Ab. The antibodies are available 
both as pre-diluted Ready-To-Use and concentrated formats. In the 
most recent NordiQC Ki67 assessment, 39.6% (162/409) of 
participants used a concentrated format of a Ki67 clone, compared 
to 60.4% that used an RTU product. 
 
Concerning controls, the international ad hoc expert committee on 
IHC at the moment recommends tonsil as IHC critical assay 
performance controls (iCAPC), where all germinal center B-cells and 
basal squamous epithelial cells must show a moderate to strong 
nuclear staining [24]. As supplementary tissues, appendix (staining 
reaction should be seen in basal crypt cells) and liver (negative 
control) are recommended. The study also underlines that the 
positive controls for Ki67 should include cells/tissues with the 
relevant clinical level of Ki67 expression [24]. 
 
2.3 Breast cancer 
 
According to the latest WHO World Cancer Report (2014), breast 
cancer is the most common cancer among women [25]. The 
incidence varies between 70 and 90 cases per 100,000 women in 
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industrialized countries. It was estimated that the number of new 
cases in 2012 was 1.7 million, and that breast cancer constituted 
25% of all cancers in women. 15% of cancer related deaths was 
attributed to breast cancer. In newly industrialized nations, both 
incidence and mortality are rising. The case fatality is highest in less 
developed countries. However, the overall mortality rates have been 
declining since the early 1990, which is attributed to earlier 
detection and more effective treatment regimes.  
For Denmark the incidence of breast cancer during 2012-16 was 
92.3, i.e., the average number of new cases was 4,700 (24.3% of 
all new cancers) [26]. The age standardized death rate (2012-2016) 
was 16.3%. During the latest 10 years with available numbers the 
death rate was reduced by 3.4%. The 1- and 5-year relative survival 
was 97% and 87%, respectively. 
 
The etiology of breast cancer is multifactorial, mostly related to 
endocrine hormonal factors related to adiposity, first delivery after 
age of 30, nulliparity, use of some contraceptives or menopausal 
hormone replacements [25]. A minor fraction of breast cancer cases 
can also be associated with genetic predispositions, namely 
mutations in the BRCA1 and BRCA2 genes. Other gene mutations 
inducing breast cancer with lower penetrance have also been 
identified.  
 
The term breast cancer covers a heterogenous spectrum of 
neoplasms both in terms of clinical behavior and histomorphological 
appearance. The diagnosis of breast cancer is most often made by 
an experienced pathologist on clinical samples such as biopsy, 
lumpectomy or mastectomy material. The vast majority of breast 
neoplasms are epithelial in origin. Often in situ lesions are seen 
alongside invasive breast cancer. 
There exists many subtypes of epithelial breast carcinomas – the 
latest WHO classification of breast tumours (2014) lists more than 
25 subtypes of carcinomas [27]. However, by far the most common 
type is the invasive ductal carcinoma, NST (no special type), which 
makes up 70-80% of breast neoplasms. This non-special subtype 
does not contain the specific morphological characteristics required 
for the other special subtypes and is the default subtype but is 
morphological heterogenous. The most common special subtype is 
the lobular carcinoma accounting for around 15% of invasive breast 
neoplasms [28]. In general, lobular carcinomas have a good 
prognosis due to low histological grade and expression of hormone 
receptors (see later). However, some studies indicate that high 
grade lobular carcinomas have worse prognosis compared to ductal 
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carcinomas, NST of the same grade [28]. Additionally, lobular 
carcinomas can be difficult to detect in screening due to a diffuse 
pattern of invasion. 
 
Breast carcinomas (of NST and lobular types) are graded based on 
the Nottingham grading system that assesses three 
histomorphological parameters of the tumour: 1) the degree of 
architectural differentiation (formation of tubules), 2) nuclear 
pleomorphism and 3) number of mitosis [29,30]. This grading 
provides prognostic information with worse prognosis for high grade 
tumours [31].  
 
Operable breast cancers are treated with either mastectomy or 
lumpectomy [32]. Systemic treatment after operation are offered to 
patients depending on the results of the pathological examination 
of the primary tumour and lymph nodes. In general, patients with 
Estrogen receptor (ER) positive tumours are treated with endocrine 
therapy except patients with very low risk of recurrence (small 
tumour, low Nottingham grade, no lymph node metastases, human 
epithelial growth factor receptor 2 (HER2) negative) [33]. Patients 
with HER2 positive carcinoma are treated with chemotherapy and 
trastuzumab. Chemotherapy are offered for patients with ER-
positive tumours and certain risk factors and/or molecular subtypes 
(see 2.5). 
 
 
2.4 Biomarkers in breast cancer 
 
Breast carcinomas are routinely examined for a number of 
biomarkers. The earliest identified was ER that is now considered 
the most important prognostic and predictive biomarker in breast 
cancer. Approximately, 75-80% of breast carcinomas are IHC-
positive for ER. ER-positive breast cancers are shown to have better 
survival than negative cancers [34,35]. In the early eighties, the 
first study was published on adjuvant tamoxifen (selective estrogen 
receptor modulator) therapy that showed improved survival in 
breast cancer [36]. Since then, it has been shown many times that 
ER-positive tumours benefit from endocrine therapy [37].  
 
Many countries (but not Denmark) also test breast carcinomas for 
progesterone receptor (PR). Since PR is a downstream effector of 
ER signaling, PR only adds little predictive information [38]. A few 
studies indicate increased benefit of endocrine therapy in ER+/PR+ 
positive breast cancers [39]. The controversial ER-/PR+ entity may 
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benefit from endocrine therapy [40], although the existence of this 
subtype has been questioned [41]. 
 
HER2 protein overexpression (as detected by IHC) and gene 
amplification (as detected by in situ hybridisation) was seen in 15-
20% of breast carcinomas in an unselected Finnish population [42]. 
It is a prognostic marker of aggressive course of disease [43]. Since 
the development of trastuzumab (anti-her2 Ab), HER2 has also 
become a predictive biomarker of response to treatment [44,45].  
 
Ki67 is an important prognostic marker in breast cancer. In a meta-
analysis of 46 studies with 12,155 patients with early breast cancer, 
the authors found significantly higher overall risk of relapse (HR = 
1.93, CI: 1.74-2.14) in patients with Ki67 positive cancers [46]. This 
was also seen when stratifying for lymph node status (negative, HR 
= 2.31; positive, HR = 1.59). Similar results were also seen for 
survival. The cutoff between Ki67 positive and negative was defined 
by the authors of the included studies. Stuart-Harris et al. published 
a review on proliferation markers in early breast cancer and found 
that high Ki67 had an impact on overall and disease-free survival 
[47].  
 
Recently, a meta-analysis of 35 studies of triple negative breast 
carcinomas (i.e., negative for ER, HER2 and PR) found that high 
Ki67 expression (cutoffs varying between 10-50%) was associated 
with lower disease-free survival (HR = 1.73, CI: 1.45-2.07) [48].  
 
 
2.5 Molecular subtypes in breast cancer 
 
In the beginning of the new millennium, a few landmark articles was 
published that identified several molecular subtypes of breast 
cancer based on hierarchical clustering of gene expression [49–51]. 
A new finding was that the ER-positive cancers could be subdivided 
into subgroups with different prognosis. They described so-called 
intrinsic subtypes were named Luminal A, Luminal B, HER2-enriched 
and Basal-like. There was significantly differently survival among 
the different groups. The HER2-enriched and Basal-like have an 
aggressive course but are responsive to chemotherapy [38]. The 
Luminal A have more favorable prognosis but is resistant to 
chemotherapy, while Luminal B are aggressive and have varying 
chemo responsivity [38]. Extensive genomic analysis have validated 
the four major molecular subgroups in regard to both genetic and 
epigenetic abnormalities [52]. 
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In a study by Cheang et al., the classical IHC markers ER, PR, HER2 
and Ki67 appeared to distinguish breast carcinomas Luminal type A 
(ER+, PR+/-, HER2-) and B (ER+, PR+/-, HER2+/-) when compared 
to gene expression profiles in a test cohort [53]. The best Ki67 cutoff 
between the two groups were 13.25%. In an independent cohort, 
Luminal A defined on the IHC classification had significantly better 
survival than Luminal B (and Luminal HER2+) [53]. Another study 
found no benefit from adjuvant chemotherapy in Luminal A breast 
cancers in cohort of high risk premenopausal patients randomized 
to either adjuvant or no treatment [54]. On the other hand, Luminal 
type B benefitted from treatment. 
 
Several commercially available genomic assays have since become 
available that based on expression of genes estimate risks of 
recurrence: Oncotype DX is a reverse transcriptase PCR assay that 
examines the expression of 16 genes related to ER, HER2, 
proliferation and invasion (and reference genes) [55]. The Oncotype 
DX produces a recurrence score between 0-100, where higher 
scores indicate a higher probability of recurrence. PAM50 is based 
on Nanostring technology with probes that bind directly to mRNA. 
The gene expression of 50 genes are measured and a Risk of 
Recurrence score and the intrinsic subtypes is reported [56].  
Others genomic assays mentioned in the literature are MammaPrint, 
EndoPredict and Breast Cancer Index. 
 
These assays are useful for identifying patients with lower risk of 
recurrence which could indicate that no adjuvant chemotherapy is 
needed. 
 
2.6 Ki67 as a surrogate marker of Luminal A 
 
Since molecular testing is not available in many clinical settings, 
pathologist and oncologists for the time need to rely on the 
surrogate IHC markers for selection of treatment regimes. It is often 
possible, based on IHC markers, to identify some of the patients 
that should be allocated to chemotherapy treatment, especially the 
triple negative and HER2-positive tumours (ER +/-) [57]. Among 
patients with ER-positive tumours, chemotherapy treatment 
decision is based on risk factors (low age, lymph node metastases 
etc.), where lymph node status seems to be the most predominant 
determinant [58]. 
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The St. Gallen international expert consensus group in 2011 
introduced a suggested Ki67 cutoff of 14% for discrimination 
between luminal type A and B based on the previous mentioned 
study with comparisons of IHC profile with the PAM50 intrinsic 
subtype [53,59]. This was in the later St. Gallen recommendations 
from 2013 changed to ”Ki67 low” for Luminal type A and “Ki67 High” 
for Luminal type B in recognition on the many clinically challenges 
in documenting this cutoff [60]. In 2015, a majority of panelists at 
St. Gallen was prepared to accept a Ki67 cutoff in 20-29% range, 
when taking in account knowledge on the local laboratory values 
[57]. A majority of panelists did not believe that multiparameter 
molecular markers were required for this distinction [57]. The 
criteria concerning Ki67 did not change in 2017 [61] although 
Luminal type B could also be classified based on high 
histomorphological grade and a “bad” molecular marker. 
Additionally, an intermediary group between luminal type A and B 
were introduced. Most recently in 2019, the St. Gallen panelist 
strongly endorsed the value of genomic assays in determining 
whether to recommend chemotherapy [62].  
 
However, the Ki67 has been challenging to score both in regard to 
separation of positive and negative nuclei but also where to score. 
Scoring reproducibility varies significantly [63] and conflicting 
studies have been published concerning hotspots versus overall 
average [64,65]. For this reason, alternative and standardized 
methods for obtaining Ki67 proliferation indices (PIs) are attractive. 
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2.7 Digital Image Analysis 
 
2.7.1 Fundamentals Digital Image Analysis 
 
Digital images can principally be separated in two fundamental 
different types: vector- and raster-images. Vector-images (e.g. 
.pdf-files) are composed of geometric shapes with information on 
individual colors and have the advances of being infinitely scalable 
and relatively small in size. On the other hand, raster-images (e.g. 
.jpeg and .tiff-files) can be considered as a large chessboard with 
stored color information in each field (pixel). For greyscale images 
(e.g. radiology images) one value is stored while several values are 
stored for each pixel in color images depending on the color model 
used. This makes stored digital images large in data size and with 
limited possibilities of zooming. Raster-images are the principal 
format recorded from digital cameras and slide scanners using in 
pathology.  
 
Digital Image Analysis (DIA) is the process of extracting information 
from raster images by analyzing the pattern of color information 
and spatial location of the pixels in a reproducible manner [66]. The 
output from DIA can take many forms: Simple measurements or 
counting of pixels, identification of regions with specific 
characteristics or complex quantification analyses of textures and 
shapes [66]. 
 
This DIA process can theoretically be split up in four analysis steps: 
preprocessing, segmentation, postprocessing and output of 
calculations [67].  
 
The purpose of the preprocessing step is to optimize the image for 
remaining analyses and reduce the complexity of the image. This is 
accomplished by different mathematical filters that remove 
irrelevant colors or noise (e.g. dust) in the image. It is also possible 
to enhance certain structures (e.g. edges) [67]. Examples of noise 
and edge-filters can be seen in Figure 2.3. 
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Figure 2.3. Image analysis algorithms applied on a grey scale image. 
Bottom row: Grey scale values. Top row: Visual interpretation. A. Original 
Image. B. Noise filter (median) applied on original image. C. Edge detection 
filter (standard deviation) applied on original Image. D. Both filters applied 
on original image. 
During the segmentation step, pixels of the image are labeled into 
groups based on common characteristics such as values in the color 
filters or spatial relation to other pixels (indirectly a measurement 
morphological characteristics) [67]. Many different segmentations 
algorithm can be used. Simple thresholds of color intensity values 
are often used to separate pixels into categories (e.g. IHC positive, 
IHC negative or background). However, thresholds can be sensitive 
to variations in staining intensity and may lose information on nuclei 
shapes [68]. Another example of segmentation is use of a 
supervised Bayesian algorithm, where the algorithm is trained 
based on pixels from different regions of interest (e.g. tumour 
tissue, normal tissue and background) [69]. The algorithm is a 
multivariate probabilistic classifier that segments all pixels on the 
similarities to the different training groups. A third example is the 
K-means clustering algorithm that unsupervised segments pixels 
into K clusters based on the Euclidian distances of the intensities in 
the color space [67].  
The postprocessing step alters the results of the segmentation and 
is used to improve the output. For example, similar pixels areas 
located closed to each other can be fused or closely situated nuclei 
detected as one can be separated. 
Finally, calculations from the algorithm are output. These are 
typically in the form of a number (number of positive/negative cells 
or areas), area (size of different categories of area) or in more 
advanced algorithms probability of certain diagnosis. 
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Finally, recent advances in machine Learning have produced 
numerous segmentation algorithms that reliably are able segment 
e.g. melanomas from nevus on par with pathologists [70–72]. One 
drawback to these artificial intelligence algorithms are the large 
dataset required for accurate training. 
 
2.8 Image analysis for Ki67 
With the recent advances in technology, many studies have 
examined the feasibility of DIA for estimation of Ki67 PIs. One of 
the first published methods was ImmunoRatio (free version closed 
2019) that was an online browser-based web application where 
users could upload IHC staining images [73]. The application 
algorithm would segment nuclei as either positive or negative and 
summary statistics including Ki67 PI. The algorithm could also be 
used for ER and PR. This method was applied in a study of 577 
breast carcinomas, where the authors found excellent correlation 
between a human observer and ImmunoRatio also in regard to a 
Ki67 cutoff of 20% (kappa 0.881) [74]. However, comparison with 
another DIA method (Cell Counter plugin for ImageJ) revealed 
significant discrepancies in categorization breast cancer (cutoff 
14%) [75]. Many commercially available algorithms are also 
available (e.g. Aperio ImageScope (Leica) and Companion 
(Ventana)). Studies have also found good correlations between 
human observers and these algorithms [76,77]. 
Applications have even been developed for smartphones mounted 
on microscopes for automatic Ki67 PI estimation which showed 
excellent correlation with both human observers and ImmunRatio 
[78].  
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3 Aims and hypothesis 
 
The general aim of this thesis was to address some of 
standardization issues that challenge the IHC marker Ki67 that is 
used for calculating Ki67 PIs, which are important in 
subclassification of breast cancer. We wanted to examine the 
applicability of DIA (specifically the VDS algorithm) as a tool for 
estimation of Ki67 PI in IHC stained slides and compare the results 
with human observers. Furthermore, we wished to examine the 
necessity of standardization in IHC staining for Ki67 in tissues 
stained with different IHC protocols. Finally, we wanted to develop 
a method for monitoring the diagnostic sensitivity of Ki67 IHC using 
DIA in standardized materials. 
 
Hypotheses 
1) Ki67 PI estimated by human observers vary significantly. 
2) Ki67 PI obtained using VDS in IHC stained breast cancers are 
similar to results from a human observer estimating Ki67 PI 
using stereological counting. 
3) Ki67 PI obtained using VDS in optimally IHC staining breast 
cancers vary depending of the primary Ab clone, format and 
stainer platform applied. 
4) On slide cell culture samples can be used as IHC sensitivity 
control. 
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4 Materials and methods 
  
This PhD project aimed to examine different phases of the Ki67 IHC 
staining and interpretation process and establish whether new or 
standardized methods could improve the quality or reliability of the 
Ki67 IHC staining and/or interpretation. 
The first study (1) was a cross sectional study on inter-observer 
interpretation variation and approaches for estimation of Ki67 PIs in 
breast carcinomas in a large cohort of clinical pathology 
laboratories. Data from the participants were compared to the 
results from the DIA Virtual Double Staining algorithm established 
in study 2. 
The purpose of the second study (2) was to compare Ki67 PIs 
estimates obtained by DIA, specifically the Virtual Double Staining 
algorithm, to a human observer. Manual estimates for Ki67 PIs was 
quantified using the current stereological gold standard (counting 
frames in systematic uniform random sampled areas). 
The third study (3) aimed to examine the impact of IHC protocol 
parameters on the Ki67 PI in a cohort of breast cancer patient. The 
included samples were stained for Ki67 (and PCK) using different 
commercially available anti-Ki67 monoclonal Abs both as 
concentrated format and ready-to-use on the most commonly used 
stainer platforms. The Ki67 PIs in the clinical tissues were obtained 
using the VDS algorithm from study 2. 
The final study (4) was a technical experiment aimed to examine 
the potential of cell lines as supplementary Ki67 IHC performance 
controls. Ki67 IHC was assessed by calculating H-scores using two 
different DIA programs. Both day-to-day variation and effect of 
suboptimal staining protocols were examined. 
 
4.1 Tissue materials 
4.1.1 Study 1 
Tissue samples from 41 breast carcinomas obtained from the 
archives of the Department of Pathology at Aalborg University 
Hospital, Denmark. After initial Ki67 IHC staining, 15 samples were 
selected from these to include breast carcinomas with even 
distribution of Ki67 PIs from 0% to 100%. The cases comprised 14 
ductal carcinomas and one lobular carcinoma. 
4.1.2 Study 2 
Tissue samples comprised 140 resection specimens obtained 
consecutively from the archives of the Department of Pathology at 
Aalborg University, Denmark. Of the 103 cases that was included in 
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the final experiment, the majority (n=83) was ductal carcinomas. 
Also included were 13 lobular carcinomas and seven other subtypes 
(combined ductal and lobular carcinoma, tubular carcinoma etc.) 
4.1.3 Study 3 
Tissue samples comprised 41 breast carcinomas obtained from the 
archives of the Department of Pathology at Aalborg University 
Hospital, Denmark. The histological subtypes of breast carcinomas 
comprised 34 ductal carcinomas, five lobular carcinomas and two 
unclassified carcinomas. The majority of all carcinomas was 
estrogen receptor positive (90.3%, 80.0% and 100% for the three 
groups, respectively). 
4.1.4 Study 4 
Cell lines were purchased from Horizon Discovery (UK) and 
consisted of three different sedimented cell cultures with different 
levels of Ki67 expression. The materials had been formalin-fixed and 
paraffin embedded and was received as TMA cores ready to be 
inserted in donor blocks. Additionally, to validate the clinical 
consequences of suboptimal protocols, the experiment also included 
slides with well characterized tissue from the NordiQC Ki67 run B22 
(breast cancer module) [23]. In brief, the clinical tissues were three 
breast carcinomas (with negative, weak and strong Ki67 
expression), liver, pancreas and tonsil. 
 
4.2 Tissue fixation and preparation 
In general, clinical material had been processed according to the 
ASCO/CAP guidelines for ER [79]. All clinical materials were 
routinely fixed for 24-48 hours in 10% neutral-buffered formalin and 
subsequently embedded in paraffin.  
 
4.3 Tissue Micro Array (TMA) 
Before construction of the TMAs, HE whole-slides of included tissue 
were screened, and areas of interest containing invasive carcinoma 
but not carcinoma in situ or normal epithelium were marked. Cores 
from the original block were drilled out using the automated 
microarray device from 3DHISTECH (Hungary). The diameter for all 
cores in study 1-3 was 2 mm. In study 4, TMA cores containing the 
clinical materials measured 4 mm, while the cell cultures measured 
2.5 mm (one core) and 1.75 mm (two cores).  
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Figure 4.1. Tissue micro array - 41 cores of breast carcinoma and one tonsil. 
All drilled out cores were transferred to recipient paraffin blocks and 
heated in an oven for 20 min. at 37°C to fuse the material. For study 
1 and 3, all cores were collected in one TMA. Due to the number of 
cores, three separate TMAs were made for study 2. 
 
4.4 Immunohistochemistry 
All IHC stains were conducted at the Department of Pathology at 
Aalborg University Hospital, Denmark. All cut slides were 3 
micrometer and mounted on SuperFrost+ (Menzel Gläser, 
Germany). 
 
4.4.1 Study 1 
Two neighboring sections were stained for either Ki67 or PCK using 
the protocol settings presented in Table 4.1. 
 
Epitope Ki67 PCK 
Antibody clone 
(dilution) 
Mib1 (RTU) AE1/AE3 (cocktail) 
(1:100) 
Vendor Dako Agilent Dako Agilent 
Stainer platform Dako Autostainer Link 
48 
Dako Autostainer Link 
48 
Epitope retrieval / 
buffer 
HIER, TRS low pH TRS High pH 
Visualisation 
system 
EnVision FLEX EnVision FLEX+ 
(mouse) 
Table 4.1. Immunohistochemical protocol parameters in Study 1. 
4.4.2 Study 2 
Two neighboring sections were cut from each TMA and staining for 
either Ki67 or PCK using the protocol settings presented in Table 
4.2. Additionally, 5 neighboring slides were stained using PCK. 
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Epitope Ki67 PCK 
Antibody clone 
(dilution) 
Mib1 (1:200) AE1/AE3 (cocktail) 
(1:100) 
Vendor Dako Agilent Dako Agilent 
Stainer platform Ventana Benchmark 
Ultra 
Ventana Benchmark 
Ultra 
Epitope retrieval / 
buffer 
HIER, CC1 HIER, CC1 
Visualisation 
system 
ultraView DAB ultraView DAB 
Table 4.2. Immunohistochemical protocol parameters in Study 2 
4.4.3 Study 3 
Commercially available, commonly used anti-Ki67 Abs were 
examined in this study, see Table 4.3. Some products were available 
both as prediluted RTU and concentrated formats (Mib1 and MM1), 
while others (SP6 and 30.9) only were sold as either concentrated 
or RTU format. For the concentrated formats, optimized staining 
protocols were developed for each stainer platform (Ventana 
Benchmark Ultra, Dako Autostainer 48 and Leica Bond) based on 
the recommendations from the international IHC ad hoc expert 
panel [80]. A single optimized PCK protocol was developed for each 
platform. During the optimization process, the concentrated format 
for the clone MM1 displayed aberrant background staining. No 
replacement was available from the vendor, and this product was 
excluded from further analysis. For each Ab clone, format and 
stainer platform combination as set of neighboring slides was 
staining for Ki67 and PCK. 
 
 
Table 4.3. Immunohistochemical staining in Study 3 (RTU: Ready-to-use) 
4.4.4 Study 4 
In order to examine the day-to-day IHC Ki67 staining variation, 
three sets of ten slides were stained on three separate days in the 
same ten slide trays on the Ventana Benchmark instrument. The 
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slides were stained using the laboratory standard Ki67 protocol 
based on Mib1 (diluted 1:200, HIER in CC1 and OptiView (Ventana) 
as visualization system). Additionally, in order to emulate 
suboptimal protocols, five sets of two slides were stained using the 
same protocol but with the Ab diluted from 1:100 to 1:1600. 
 
 
Figure 4.2. Immunohistochemical staining for Ki67 of a breast carcinoma 
(mAb clone SP6). 
 
4.5 Digitalization of stained slides 
All slides were digitized using a NanoZoomer XR (Hamamatsu 
Photonics, Japan) at the highest resolution (40x). Regions 
containing tissue were manually selected, while the scanner 
automatically identified a single focus plane.  
 
4.6 Digital Image Analysis 
4.6.1 Virtual Double Staining 
The VDS algorithm was developed for IHC quantification of different 
breast cancer related epitopes (HER2, ER, PR and Ki67). The 
purpose of the VDS is to limit analysis to tumour cells only. Similar 
to many physical double stains, the VDS utilizes one IHC staining 
reaction for identification of cells of interest and a second for 
quantification. However, the algorithm requires two separate IHC-
stained slides. In the studies included in this thesis, slide pairs were 
stained for PCK (for detection of tumour areas) and Ki67 
(quantification). 
The VDS algorithm consists of three fundamental steps: First, the 
algorithm aligns the two slides so that tissue structures will be as 
parallel as possible. This is obtained using rotation and local 
deformation of the image. Secondly, tumour areas are detected in 
the PCK stained slide. This part of the algorithm is based on a 
Bayesian classifier with stored training information. Finally, cell 
nuclei (when applied for Ki67) are detected and segmented to either 
IHC positive or IHC negative. The algorithm could also split up the 
positive cells into three categories (based on the intensity / 
“brownness” of the IHC reaction).  
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Two of the authors (MV and RR) from the studies in this Ph.D. study 
participated in the development of the algorithm – specifically by 
submitting images manually marked with Ki67 positive or negative 
cells and by reviewing initial results from the algorithm. After this 
initial phase, the algorithm was locked (and commercially 
available). Hence, the exact Image Analysis steps used for this cell 
segmentation are not available. However, the developer has stated 
segmentation of nuclei is based on threshold of the mean intensity 
of pixels detected in a nucleus. 
 
 
Figure 4.3. Virtual Double Staining principle. Left: Slide stained for Pan 
Cytokeratin (PCK). Regions of interest (PCK-positive) are detected and 
transferred to second slide. Right: Ki67 stained slide. PCK-negative areas 
are ignored (green), while Ki67 positive (red) and negative (blue) are 
counted. 
The complete VDS algorithm was applied on breast cancer tissue in 
study 1-3. Additionally, both Ki67 PIs and H-scores were calculated 
in study 3. The main focus in study 4 was Ki67 expression and since 
the cores only contained cells of interest, image analysis using VIS 
was limited to the Ki67 segmentation and H-score step. 
 
In order to examine the proficiency of VDS alignment of slides and 
importance of spatial distance between slides, five neighboring PCK-
stained slides were virtually aligned using to VDS algorithm (study 
2). An adapted version of PCK algorithm compared both neighbor 
(1-2, 2-3, 3-4 and 4-5) and non-neighbor slide pairs (1-3, 1-4 and 
1-5), and segmented the fused image as “PCK-positive in both slides 
(+/+)”, “PCK-negative in both slides (-/-)” or PCK-positive in one 
slide (+/-) / (-/+)”. 
 
4.6.2 QuPath – study 4 
A second DIA program was included in study 4 to examine the 
consistency in both the estimated Ki67 PIs and H-scores between 
different algorithms. The program QuPath (University of Edinburgh) 
was selected since it was freely available, had open source code and 
was specifically developed for pathological images [81].  
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The program has an inbuild cell detection algorithm that can 
segment nuclei in IHC stained slides and provide a cell count, 
fraction of positive cells (Ki67 PIs) and H-score based on three 
categories of positivity. All algorithm parameters were the default 
of the program, except for “Detect Image” where “Optimal density 
sum”, since this parameter qualitatively gave better separation of 
individual nuclei. 
 
4.7 Manual scoring 
Unless otherwise indicated, Ki67 PIs were calculated as the fraction 
of positive tumour cells (nKi67 positive tumour cells / ntumour cells) in all studies. 
A Ki67 positive tumour cell was qualitatively defined as a cell 
nucleus with an unequivocal IHC staining reaction regardless of size 
or staining intensity. 
 
4.7.1 Online scoring module – Study 1 
In order to examine interobserver variability in K67 PIs estimation, 
a survey module was created online as part of the run B18. The 
module was hosted by PathXL (now purchased by Philips and 
renamed Philips Tutor) and included 15 scanned tissue cores of 
breast carcinoma. All participants in the NordiQC breast cancer 
module (n=417) were individually invited to participate. Apart from 
scoring Ki67 PIs, participants were asked on their method of Ki67 
PIs estimation (counting vs. eye balling, hot spot vs. average), job 
title, clinical control tissue and whether they considered weakly and 
moderately Ki67 stained nuclei as Ki67 positive. 
The participants had one month to complete the challenge. After 
completion of the module, participants received individualized 
feedback on their scoring compared to the overall results. 
 
4.7.2 Manual stereological scoring – Study 2 
All breast carcinoma cores were manually assessed for Ki67 PIs. 
Due to the large number of tumour cells in every core, a number of 
areas were sampled according the Systematic Uniform Randomized 
Sampling-principle. This step was performed automatically in the 
VIS-program (Visiopharm A/S, Denmark) using the newCast 
function. The computer randomly placed a grid of counting frames 
on each of the cores. All tumour cells within the counting frames 
was marked as either Ki67 positive or Ki67 negative by a specially 
trained pathologist (RR). Specifically, cell profiles within the 
counting frame or touching the upper or right border were included, 
while cells touching the lower or left border were excluded in order 
to prevent overestimation of cell profile numbers [82]. Complicated 
cases were discussed with a senior colleague (MV). The counted 
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number of positive and negative cells could be extrapolated to a 
Ki67 PI estimate of the whole core. 
 
Figure 4.4. A. Systematic Uniform Random Sampling (SURS). Grid 
randomly placed on a breast cancer tissue core. B. Counting frame on a 
Ki67 IHC stained slide. Each cell within the frame were manually marked 
as Ki67 positive or negative. 
4.7.3 Quality scores – study 4 
The staining quality was assessed in the clinical tissues incorporated 
in the TMA in study for (see 4.1.4 for composition). An adapted 
NordiQC scale was applied with the marks: Optimal, Good and 
Insufficient [83]. Slides were marked according to adherence to the 
criteria set for Ki67 stained slides in NordiQC Ki67 run B22 [23]. 
 
4.8 Statistical analyses 
Data preparation and statistical analyses were performed in R 
(various versions) with the graphical user interface RStudio (various 
versions) installed. All data formatting and calculations were 
performed using reproducible scripts (available on request) [84]. 
Figures were created using the ‘ggplot2’ package (implementation 
of Grammar of Graphics) [85]. In boxplots, boxes represent the 
inter quartile range (IQR), central lines represent median and 
whiskers represent the most extreme data points within 1.5 IQR 
[86]. Data points outside this range were considered outliers and 
represented by dots. In some plot, outliers were removed from plot, 
but not underlying statistical calculations, to enhance the visual 
interpretation. P-values lower than 0.05 were considered 
statistically significant. H-scores were calculated using the formula: 
 
H = Fweak + Fmoderate x 2 + Fstrong x 3, where F = fraction of cells 
 
The following subsections will briefly introduce statistical methods 
only used in some of the studies. 
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4.8.1 Study 1 
Ki67 PIs between two or more subgroups were compared using 
either Mann Whitney U-test or Kruskal-Wallis test. Multivariate 
analysis was performed using factorial ANOVA. Level of agreement 
between groups when separating in Ki67 Low or Ki67 High was 
examined using Fleiss’ kappa. Intra Class Coefficients (ICC) for 
estimation of agreement between the two methods were calculated 
using the ‘psych’-package for R. 
 
4.8.2 Study 2 
R2 was calculated using the ‘lm’ function in R. Bland-Altman plots 
visualize the mean value of the methods (x-axis) versus the 
difference between the two methods (y-axis) [87]. ICC was 
calculated as in study 1 (see 4.8.1). 
 
4.8.3 Study 3 
Comparisons of Ki67 PIs and H-scores between groups were 
accomplished using either ANOVA (with post hoc test: Tukey HSD) 
or Kruskal-Wallis test (post hoc test: Dunn). ICC was calculated as 
in study 1 (see 4.8.1). 
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5 Results 
In the sections below, I will briefly summarize the main results 
presented in the individual studies. 
 
5.1 Study 1 
199 individual participants completed the Ki67 scoring webmodule. 
Data from 77 cores (2.5%) had not been filled in. This was not 
related to any specific core. In general, there was a moderate to 
high level of agreement in Ki67 PIs between the observers with an 
ICC of 0.85. 
 
 
Figure 5.1. Ki67 scoring by 199 participants. Box plots show the variation 
of scoring. Red line indicates the suggested cutoff 20%. Numbers above 
each box plots show the percentages of participant scoring a core as Ki67 
High (=> 20%). (Adopted from Røge et al. Ki67 Proliferation Index in 
Breast Cancer as a Function of Assessment Method. A NordiQC Experience. 
Appl Immunhistochem Mol Morphol (Study 1)). 
However, six cores (2,4,11-13 and 15) were challenging for the 
participant. In these, more than 20% of the participants categorized 
the tumour differently from the majority. The highest level of 
disagreement was seen in core 12, where 50.3% categorized this 
as Ki67 Low. All cores with a high level of disagreement had mean 
Ki67 PIs close to the cutoff (20%). 
 
There was statistical difference in K67 PIs between observer that 
were senior pathologists compared to residents in pathology (see 
Figure 5.2). Observers that scored Ki67 PIs in “hot spot” had higher 
Ki67 PIs compared participants estimated the overall average. 
Likewise, observers that considered weakly Ki67 stained nuclei as 
positive provided higher Ki67 PIs than those who did not. Manual 
counting (as opposed to eyeballing) provided statistically significant 
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higher Ki67 PIs (see Figure 5.2). However, there was no significant 
difference in Ki67 PIs depending on the number of cells counted 
(100, 200 and 500 cells). When counting more than 1,000 cells, 
Ki67 PIs tended to be lower, although this was not statistically 
significant (for most cores). 
 
 
Figure 5.2. Comparison of Ki67 PIs estimates stratified by: A. Job title, B. 
Method for Ki67 PI estimation. (Adopted from Røge et al. Ki67 Proliferation 
Index in Breast Cancer as a Function of Assessment Method. A NordiQC 
Experience. Appl Immunhistochem Mol Morphol (Study 1)). 
The results of the participants that estimated the overall average 
were compared to data obtained from the VDS algorithm. There was 
a deviation from the average of the participants and VDS between 
0.1 and 5.8%. When applying the 20% cutoff, VDS categorized all 
carcinomas except two (2 and 11) as the majority of participants. 
 
 
Figure 5.3. Ki67 PIs estimated in 15 breast carcinomas by participants 
(scoring the overall average of the core) compared to results from Virtual 
Double Staining (Red dots). (Adopted from Røge et al. Ki67 Proliferation 
Index in Breast Cancer as a Function of Assessment Method. A NordiQC 
Experience. Appl Immunhistochem Mol Morphol (Study 1)). 
 
The participants reported that they most commonly (48.3%) used 
some form of lymphoid tissue (tonsil, lymph node or appendix) as 
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external IHC control. A large group (33.7%) did not use external 
controls at all. 
 
5.2 Study 2 
Of the 140 breast carcinoma cores included in this study 103 was 
analyzed further. 37 cores were excluded due to missing tissue, 
small tumour areas or folding. The VDS algorithm was applied both 
on the areas sampled for manual Ki67 PI estimation and the whole 
core. In the sampled areas, the VDS on average identified 14.1 % 
fewer cells than the human observer. 
 
Overall, there was a good correlation between the human observer, 
counting using stereological counting frames, and the VDS 
algorithm (see Figure 5.4). The R2 for linear fit was 0.96. All relevant 
ICC were above 0.98 (CI: 0.97-0.99). Although there was a small 
tendency to lower Ki67 PIs when using VDS (mean difference 
0.4%), Bland-Altman plots did not reveal any skewness in any data 
ranges (see Figure 5.4). Similar results were obtained when 
comparing the human observer with VDS obtained on the whole 
core (and not just sampled areas). 
 
 
Figure 5.4. Comparison of Manual Ki67 estimation and Virtual Double 
Staining in the same sampled areas obtained by Systematic Uniform 
Random Sampling. A. Correlation plot. B. Bland-Altman plot. (adapted from 
Røge R. et al. Proliferation Assessment in Breast Carcinomas Using Digital 
Image Analysis Based on Virtual Ki67/cytokeratin Double Staining. Breast 
Cancer Res Treat, 158 (1), 11-19. (study 2)) 
Area overlap between neighboring slides where examined in five 
serial sections stained for PCK. The mean area overlap between 
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neighboring sections was 91% (range 82%-98%). Overlap 
decreased by distance between slides. 
 
 
Figure 5.5. Overlap between to neighboring slides stained for PCK. Colors 
indicates PCK area status in the two slides: Red, PCK-positive in both slides. 
Yellow, PCK-negative in both slides. Blue/green, PCK-positive in one of the 
slides. (Adapted from Røge R. et al. Proliferation Assessment in Breast 
Carcinomas Using Digital Image Analysis Based on Virtual Ki67/cytokeratin 
Double Staining. Breast Cancer Res Treat, 158 (1), 11-19. (study 2)) 
When assuming a Ki67 cutoff point of 20%, the human observer 
classified 74% of the carcinomas as Ki67 Low. In comparison, the 
VDS-algorithm categorized 75% of the tumours as Ki67 Low. 
 
5.3 Study 3 
38 of the 41 included tissue cores were adequate for further analysis 
(three cores were excluded due to damaged/missing tissue or 
background staining PCK staining). It was observed that 
significantly fewer cells were detected when slides were stained on 
the Ventana Benchmark Ultra platform (mean 4.4% fewer than the 
overall average). 
 
Differences in Ki67 PIs (percentage points=pp) obtained by 
comparing the results from the VDS algorithm to the overall average 
(for each individual core) are presented in Figure 5.6 for the 
different clone, format and stainer platform combinations.  
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Figure 5.6. Absolute difference (percentage points = pp) in proliferation 
indices between the most commonly used antibody clones, formats and 
stainer platforms. The numbers represent the absolute deviation from the 
overall average. (adapted from Røge et al. Impact of Primary Antibody, 
Format, and Stainer Platform on Ki67 Proliferation Indices in Breast 
Carcinomas. Appl Immunohistochem Mol Morphol, 27 (10), 732-739. (study 
3)). 
The commonly used mAb clone Mib1 as a concentrated format 
obtained similar Ki67 PIs as the overall average on the Dako 
Autostainer and Leica Bond platforms. On the Ventana Benchmark 
Ultra, concentrated Mib1 provided an average Ki67 PI 2.2 pp lower 
than overall average. The RTU format of Mib1 applied on the Dako 
Autostainer had 8.6 pp lower Ki67 than the overall average. 
Similar results were seen for the concentrated SP6, except on the 
Ventana Benchmark platform where 11.9 pp higher Ki67 PIs were 
seen. The MM1 clone, only available as RTU for the Leica Bond 
stainer, provided the lowest Ki67 PIs – on average 12.5 pp lower 
than the overall average. The rmAb 30.9, only available as RTU for 
the Ventana platform, obtained the highest Ki67 PIs namely 10.4 
pp higher than the overall average.  
 
Figure 5.7. Ki67 stained breast carcinoma using: A. Concentrated mAb SP6 
on Ventana Benchmark Ultra (overall average Ki67 PI 38%). B. RTU MM1 
on Leica Bond (overall average Ki67 PI 12%). 
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In general, the results showed significant variations in Ki67 PIs 
between the different clones, formats and stainer platforms. 
 
The study also compared H-scores, which showed similar results as 
the Ki67 PIs. Using the suggested cutoff of 20% between Ki67 Low 
or High tumours (Luminal type A and B), the proportion of Ki67 High 
carcinomas was 63%. If the MM1 RTU products was applied on the 
Leica Bond platform, 42% were classified as Ki67 High. On the other 
hand, using either clones 30.9 or SP6 on the Ventana Benchmark 
platform, 76% of carcinomas were Ki67 High. 
 
5.4 Study 4 
The day-to-day variation in H-scores for the three cell lines were 
low. The coeffiecient of variation was below 5% for all cores and 
methods (except one core using QuPath) (see Figure 5.8). 
 
 
Figure 5.8. Day-to-day variation in H-scores in three cores of cell lines 
(n=10). H-scores obtained using QuPath. (Adapted from Røge et al. Image 
Analyses Assessed Cell Lines as Potential Performance Controls of Ki67 
Immunstained Slides. Appl Immunhistochem Mol Morphol (Study 4)). 
H-scores decreased with increasing dilution of the primary Ab 
(imitating suboptimal staining protocols). On average, decreasing 
the Ab concentration to 50%, 25% and 12.5% decreased the H-
scores 20.1%, 35.5% and 57.5%, respectively. It was possible to 
visually select cutoff for each cell lines that separated optimally and 
suboptimally stained slides (see Figure 5.9). 
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Figure 5.9. H-scores in three cell cultures staining using a range of primary 
antibody (Mib1) dilutions and quantified using VIS (Visiopharm A/S). 
Boxplots are coloured depending on the assessed quality of the clinical 
tissue on the slide. The dashed lines show proposed H-score cutoffs 
between optimally and suboptimally stained slides. (Adapted from Røge et 
al. Image Analyses Assessed Cell Lines as Potential Performance Controls 
of Ki67 Immunstained Slides. Appl Immunhistochem Mol Morphol (Study 
4)). 
The VIS platform detected 14-18% less nuclei than the QuPath 
algorithm. There was a tendency to higher H-scores using the VIS 
DIA program, although this difference was not statistically 
significant. 
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6 Discussion 
 
Estimation of Ki67 PIs has still not been widely adopted in clinical 
diagnostics of breast cancer despite a plethora of studies indicating 
that Ki67 possesses prognostic and predictive information. The main 
challenge for implementation of this potential biomarker is the lack 
of standardization in both Ki67 IHC procedures and interpretation of 
the results. The general purposes of this PhD project were to 
elaborate on some of these standardization challenges and examine 
possible solutions. 
 
We examined the inter-observer variability and methodology for 
Ki67 PI estimation in a large cohort of human observers (Study 1) 
and found significant variations in both Ki67 PI results and scoring 
methodology. We then validated a new DIA algorithm, Virtual 
Double Staining, for Ki67 PI estimation by comparison to a human 
observer that used the current stereologically gold standard (Study 
2). Additionally, we applied DIA to examine the influence of IHC 
primary Ab, format and stainer platform on Ki67 PI and found 
significant differences between the different combinations (study 3). 
Finally, we examined cell lines assessed by DIA as potential IHC 
performance controls (Study 4). 
 
6.1 Ki67 estimation in a human cohort (Study 1) 
The principal findings of study 1 was significant differences in Ki67 
PI obtained by the participants in the same 15 breast cancer cores 
available as digital images in a webmodule. The participants used 
different methods for obtaining Ki67 PIs both in terms on how 
(eyeballing or manual counting of a number of cells) and which area 
(overall estimate or hotspots) they scored. Participants that counted 
manually and/or scored in hotspots tended to have higher Ki67 PIs. 
 
There was a good correlation between the Ki67 PIs among the 
participants (ICC score 0.85), but when applying a cutoff (20%) 
only moderate kappa-values were achieved. This is in line with other 
inter-observer studies of Ki67: Shui et al. examined the inter-
observer variations among five pathologists estimating Ki67 PIs in 
160 breast carcinomas and found an ICC of 0.904 when assessing 
the overall Ki67 PI average [88]. However, when categorizing in 
three Ki67 intervals, agreement was significantly lower for tumours 
close to 20%. Similar results has been reported by other groups 
[63,89,90]. A recent study by the Danish Breast Cancer Group 
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(DBCG), found, as we did, higher Ki67 PIs when scoring in hotspots 
rather than the overall average [91]. As in our study, Focke et al. 
found significantly higher Ki67 PI when examining in hotspots and 
counting fewer cells [92]. 
 
To the best of our knowledge, this is the largest study that 
compared the observer’s job title (as an indirect measure for 
experience). We found no significantly different Ki67 PIs and similar 
variations which somewhat controversially indicated that pathology 
experience was less important. However, this could also be related 
to recruited participants that were all contact person in the NordiQC 
breast cancer module and hence possibly had experience with 
breast cancer and Ki67 PI estimation regardless of their position. 
Additionally, the circulated material consisted mostly of ductal 
carcinomas in which neoplastic cells tended to be easier to identify 
morphologically than in e.g. lobular carcinomas. 
 
The study used centrally stained slides in order to limit the 
variability of the Ki67 PI estimation to the interpretation of the IHC 
stained slide and not variability in IHC assays. However, it was 
performed digitally which is not the standard microscopy method in 
most laboratories and hence Ki67 PI could have been influenced by 
the quality and brightness of local computer monitors. A few studies 
comparing computer monitors and conventional microscopy found 
comparable results in mitotic counts and indicate that this may be 
of minor importance [93,94]. 
 
The participants were asked to score the virtual slides using their 
standard method and had not received any previous guidelines. Our 
results probably reflect variations in both scoring and scoring 
methodology in clinical pathology laboratories. Large efforts have 
been made internationally to develop scoring systems that could 
standardize the post-analytical phase of the Ki67 IHC stain. The 
International Ki67 Working Group developed a standardized scoring 
procedure in TMAs, where 250 cells from both the top and bottom 
of each core was scored [95]. Sixteen laboratories had been trained 
in the method before the study. The study achieved an impressive 
ICC of 0.94. Similar results were later obtained for core-cut biopsies 
and tissue sections [96,97]. These results indicate that standardized 
scoring systems may decrease inter-observer variability. 
 
6.2 Digital Image Analysis (Study 1-3) 
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In study 2, we investigated the applicability of DIA, specifically VDS 
for Ki67, by comparing results obtained from the algorithm with a 
human observer estimating Ki67 PI using stereological counting 
frames in Systemic Uniform Random Sampled areas in 140 breast 
carcinomas. The ICC for the correlation between the two methods 
was 0.98 (CI: 0.97-0.99) indicative of an excellent correlation 
according to Koo et al. [98]. 
 
On average the VDS detected 14% fewer cells than the human 
observer. Qualitative examination of slides revealed that the 
algorithm sometimes missed small, weakly stained nuclei (DAB and 
hematoxylin) and nuclei outside the regions of interest that had 
been excluded due to small misalignments of the slides. Our 
experiment with agreement of alignment showed that overlap 
between slides decreased significantly in non-neighbouring slides 
which affected especially diffusely infiltrating tumours more than 
solid tumours. It is essential that slides used for VDS are 
neighboring slides which may require an update laboratory 
workflow. Even in well aligned slides one must expect small changes 
in the neoplastic area which will include stroma cells in the regions 
of interest and hence dilute Ki67 PI with stromal cells (that most 
commonly have lower Ki67 PI). 
 
Normal glandular epithelium and carcinoma in situ (CIS) are also 
positive for PCK and would be included in the tumour regions of 
interest. In this study, we selected tumour areas without normal 
epithelium and CIS, but this is often not possible in clinical settings, 
which could prevent unsupervised analysis. One possible solution 
for this could be inclusion of basal cell markers (e.g. p63 and/or 
heavy chain smooth muscle myosin) in a virtual triple stain, where 
glands with positive staining for basal markers are excluded. 
 
In the same manner, tumour infiltrating lymphocytes (TILs) will be 
included in the regions of interest if located among the neoplastic 
epithelial cells. If the number of lymphocytes is high and they have 
a Ki67 PI deviating from the neoplastic cells they could influence 
they final result. Especially medullary carcinomas have high Ki67 
PIs and contain many lymphocytes [99]. We had included two 
medullary carcinomas in this study. The human observer scored 
higher Ki67 PI in one of the cases and lower in the other. Hence, 
the question on influence of TIL remains and warrants further 
studies for clarification. 
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The literature shows that many well-functioning algorithms for 
estimation of Ki67 PIs are available. The main drawback with many 
of these algorithms is lack of tumour recognition and requirement 
for manual selection of regions of interest. This is time consuming 
especially for whole slide sections. One group addressed this by 
using physical double stains in melanomas (Mart1/Ki67) and breast 
cancer (KL1/Ki67) [100,101]. However, the authors found lower 
Ki67 PI in physcial double stains when comparing to single stains 
which may be due to overlapping of the chromogens. 
 
One limitation to study 2 is the comparison with a single human 
observer. Since the human observer (RR) participated in the 
development of the algorithm, this may be optimized to his 
interpretation of Ki67 positive and negative cells. For this reason, it 
would be important to validate the algorithm to a larger cohort of 
observers. 
 
To achieve this, we applied the VDS algorithm on the digital slides 
scored by the participants (that scored an overall average) in Study 
1 and found that VDS Ki67 PIs were similar to the mean (see Figure 
5.3). Although this is a crude comparison, wisdoms of crowds has 
been a well-established concept since Francis Galton’s famous 
experiment at a livestock fair, where the median of the attendees’ 
guesses correctly predicted the weight of an ox [102]. 
 
The VDS approach has since publication of Study 2 also been 
examined in whole slide images of breast carcinoma using two 
different platforms (Visiopharm and Indica labs). The authors found 
good correlations with manual counting on both platforms [103]. As 
in our study, a rather large number of tissues had to be excluded 
due to folding of tissue which puts greater demands on laboratories 
for optimal slides and require special training of laboratory 
technicians. Additionally, a large study examining accuracy in 
detection of PAM50 validated Luminal B subtypes showed that VDS 
outperformed human observers [104]. The authors examined VDS 
estimated Ki67 PI as an overall average both also in hot-spots and 
in the invasive margin and found that hot spots had slightly better 
prognostic value. In a recent study, the group confirmed that Ki67 
PI estimated by VDS outperformed manual observers (especially in 
hot spots) in classification of luminal type and with regard to 
prediction of overall and relapse-free survival [65]. 
 
Study 2 did not examine Ki67 in hot spots or the invasive margin 
but rather the overall average. There is no reason to expect that our 
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validation of the segmentation of Ki67-positive and negative nuclei 
cannot be extrapolated to estimation in invasive margins or hot 
spots. Hot spots are detected mathematically after the nuclear 
segmentation [105] and invasive margins are based on a manual 
selection of ROI. 
 
In study 3 we examined the impact of different Ki67 mAb clones, 
clone formats and stainer platforms on Ki67 PI and H-scores in 41 
breast carcinomas obtained by VDS. The results for Ki67 PIs and H-
scores were relatively similar. The principal finding was significantly 
different Ki67 PI when using different primary Ab clones or formats. 
Additionally, results were platform related for some clones. 
 
The results indicated that Ki67s are comparable when using the 
concentrated format of Mib1 and SP6 on the Dako Autostainer or 
Leica Bond (using optimized protocols). On the Ventana Benchmark 
platform, the Mib1 clone provided lower PIs, while the mAb clones 
SP6 and 30.9 gave higher results. This could potentially be related 
to the sensitivity of the individual visualization system to different 
Ab types. SP6 and 30.9 are both raised in rabbits, while Mib1 is a 
mouse monoclonal Ab. The RTU format of the Mib1 provided lower 
Ki67 PIs, indicating that the overall sensitivity of the RTU system 
and clone is lower than in-house optimized protocols. This could 
perhaps be related to the Ab concentration in the RTU product. 
 
Our results are in line with other studies comparing Ki67 IHC Ab 
clones: Fasanella et al. compared the SP6 and MM1 antibodies 
stained on Dako Autostainer 720 and Leica Bond Max [106]. The 
authors found significantly higher Ki67-scores when using SP6 
although the antibodies were not directly compared. Instead, two 
consecutive breast carcinomas cohorts were stained using SP6 or 
MM1 and summary statistics compared. Another group compared 
the Mib1 and MM1 clones in normal and neoplastic tissues and 
found, as in study 3, that the Mib1 clone provided significantly 
higher Ki67 PIs [107,108]. Both studies are rather old and the IHC 
was performed on a now outdated machine with obsolete 
visualization systems, which makes comparison to our study less 
relevant. Another study by Ekholm et al. examined the prognostic 
value of Mib1 and SP6 Ab clone and found that clones were 
comparable in detecting distant disease-free survival [109]. As in 
the previous studies, the IHC was performed on an older platform 
with an outdated biotin-avidin detection system. One group also 
compared the Mib1 and SP6 clones and their ability to predict 
progression of advanced disease and found comparable results for 
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the clones [110]. The authors also concluded that the Mib1 clone 
was less suited for DIA due to significant background staining. We 
did not experience such background issue and suspect that the 
background staining in more likely related suboptimal staining 
protocols rather than the Mib1 clone itself. 
Focke et al. compared thirty European laboratories that stained 
serial sections from the same breast carcinoma TMA using their in-
house Ki67 protocol [90]. Slides were assessed centrally by one 
human observer. Significant differences were observed: The 
proportion of luminal type A varied from 17-51%. The variance 
remained when splitting up the laboratories depending on the 
primary Ab clone applied. This is most likely caused by suboptimal 
protocols being employed by some of laboratories. Although the 
study incorporated “participation in an external QA program” as a 
parameter, a better parameter for future studies could perhaps be 
“performance in external QA programs”. Only optimized protocols 
were applied in our study. 
 
All aspects of Ki67 estimation from preanalytics to IHC staining and 
interpretation must be considered when trying to optimize the Ki67 
test. Going through the literature, enormous efforts have been 
made to examine and expand on the interpretation. Conversely, 
only relative few studies have been made concerning the Ki67 IHC 
protocols and preanalytics. In our opinion, significantly greater 
efforts should be devoted to developing standardized IHC methods 
that no doubt will ease interpretation. 
 
We observed a significantly lower number of cells detected on the 
Ventana Benchmark platform. This could be related to either smaller 
areas detected or fewer nuclei. Data showed that the PCK-stained 
areas were similar in size across the different platform. If the 
algorithm systematically detected fewer negative cells (due to 
weaker counterstaining), this could potentially explain some 
increases in the Ki67 PIs on the Ventana platform. However, 
qualitative assessment of the Ki67 stained slides did not reveal any 
platform related drops in cell counts. Theoretical calculations 
showed that a loss of 10% negative cell on average only would 
increase the Ki67 PI by 0-3%. We do not find that the increased PIs 
in the two clones 30.9 and SP6 on the Ventana platform can be 
explained by this phenomenon. Especially when the Mib1 clone 
yielded lower PIs.  
 
Although we could not provide any explanation for the difference in 
cell counts, it is most likely related to small difference in the staining 
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intensity of both DAB and hematoxylin. This underlines the 
necessity of calibrations of DIA algorithms. In this study, it was not 
possible to optimize the algorithm for each stainer platform and 
visualization system that uses hematoxylin and DAB with nuance 
differences in staining color. Internal data from a DIA experiment of 
slides stained by the NordiQC participants showed that the wide 
variety of intensities in DAB and hematoxylin prevented analysis. In 
recognition of this, it has since become possible to adjust the VDS 
algorithm to laboratory specific intensities by use of reference 
materials. 
 
The color calibration of the image capture devices as slide scanner 
can also impart the outcome of DIA algorithms. In the context of 
this project, slides (a TMA with 41 breast carcinomas) were scanned 
using different color profiles on the scanner before and after color 
calibration of the scanner (data not presented). Although no 
statistical significance could be obtained, there was a tendency 
towards different results before and after calibration. The potential 
source of error would not affect the results in this thesis, since all 
slides for an experiment were scanned in one batch. However, it is 
necessary to take this in account when comparing digital slides from 
different institutions, scanner manufacturers and achieved material. 
This problem has also been recorded in the literature and is 
potentially solvable using on slide color controls [111].  
 
 
6.3 Immunohistochemistry controls (Study 1 and 
4) 
 
In study 1, the most common (48%) control tissue among the 
NordiQC participants was lymphoid tissue (tonsil, lymph node or 
appendix), while a rather large group (38%) stated that they did 
not use control tissue or internal controls. This finding is not 
surprising since it well known that many clinical pathology 
laboratories still do not use on-slide controls. IHC reactions without 
on-slide controls, will, in the potential absence of internal positive 
cells, prevent the pathologist from knowing if the IHC reaction 
succeeded. 
 
In study 4, we showed that cell lines stained for Ki67 and assessed 
by DIA provided rather stable day-to-day H-scores. Additionally, H-
scores reflected the technical sensitivity in assays with simulated 
suboptimal protocol parameters. This allowed identification of 
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cutoffs in H-scores that reliably identified suboptimal staining 
protocols. 
 
To the best of our knowledge, this is the first study that examined 
the potential of cell lines as performance controls in Ki67 
immunostained slides. Cell lines engineered to express certain 
epitopes are often used in academical laboratories as controls. 
However, this method is more seldomly used in laboratories with 
access to clinical tissues. Previously, cell lines have been suggested 
as performance controls for HER2, although this method has not yet 
been incorporated in daily practices [112]. The authors identified 
cell lines with (and without) HER2 gene amplification and 
corresponding 3+ and 2+ IHC reaction.  
 
When selecting controls for IHC experiment it is imperative that 
tissues include the clinical relevant range of epitope expression 
[24,113]. Tissue with very high or very low levels of epitope 
expression will provide only little information about the sensitivity 
and successfulness of the reaction. The cell lines examined in study 
4 consisted of cells with varying Ki67 expression ranging from weak 
to strong. 
Cell lines cannot be used alone as external IHC controls, since they 
would only monitor the sensitivity, and must be supplemented with 
other tissue for specificity and preanalytics. 
 
One extreme data point obtained using QuPath (core C) was below 
the cutoff. Visual inspection of this core revealed only strongly 
positive and negatively stained cells indicating that the IHC reaction 
to some degree had failed. Score obtained on the second platform 
for this core was also low (but not below the cut-off value). 
 
One of the strengths with this study was the use of two different 
DIA platforms (one commercial and one open source) for obtaining 
H-scores. Although one platform systematically identified more cells 
than the other (and reported lower H-scores), there was good 
correlations between the results obtained by the two platforms. If 
the cell lines and DIA were applied in a clinical laboratory as a 
clinical sensitivity surveillance system, deviations from 
predetermined H-scores range would be the primary benchmark. 
Using both platforms, it was possible to identify H-score cut-offs 
that could identify suboptimally stained slides. For this reason, both 
platforms can be used. Previously, we examined the potential of 
using cell lines as quality indicators in a NordiQC Ki67 run using a 
custom developed algorithm [114]. The algorithm showed great 
 49 
promise in a test set (forty cases), but this could not be extrapolated 
to the whole cohort due to significant differences in color intensities. 
This indicates that the cell lines and DIA H-score as sensitivity 
surveillance system may be limited to intra-laboratory surveillance 
and not inter-laboratory comparisons. 
 
One limit of the study was the rather small number of samples 
examined. This proof of concept should be validated by further 
studies. The method could potentially be expanded to encompass 
other nuclear markers as ER, PR, Sox10, Bcl-6 and Pax8 provided 
that relevant cell lines with clinically relevant expression ranges can 
be found. 
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7 Conclusions 
 
In this PhD study we examined the current practices on Ki67 scoring 
in breast cancer in a large cohort of clinical pathology laboratories 
and found significant differences. Additionally, we saw variations in 
Ki67 scoring depending on the methods used. This underlines the 
need for standardization since variations may impact the treatment 
decision in patients. 
 
DIA for obtaining Ki67 PIs is possibly one such standardization step. 
We validated the VDS algorithm to a human observer and found 
good correlation between Ki67 PIs obtained by the human observer 
and DIA. After further validations, this algorithm could possible by 
applied in clinical practice. 
 
We applied the algorithm to compare Ki67 PIs in clinical tissues 
stained with different antibodies, formats and stainer platforms and 
found significant differences in Ki67 PIs when applying different 
combinations. One major focus of Ki67 in breast cancer has been 
the interpretation of stained slides. Our results show that more 
attention should be given to the IHC analysis itself, since the 
variations introduced in this step is just as large as by interpretation. 
 
Finally, we introduce a novel method for monitoring the 
performance sensitivity of Ki67 IHC stained slides. Using cell lines 
and DIA it was possible to detect suboptimally stained slides. 
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8 Future perspectives 
 
The studies included in this thesis have generated questions for 
further research. 
 
The large variation in scoring methods observed in study calls for 
international standardization of counting methods. Likewise, the 
question on where to score remains. Some studies indicate that Ki67 
hot spots provide better predictive information than the overall 
average. However, definitions on hot spots vary and should be 
harmonized in coming studies validating this. 
 
The VDS algorithm has also been examined by other groups that 
proved that the algorithm worked on whole slide tissue and was 
better in predictions of survival [65,103,104]. However, it would be 
interesting to see comparisons of VDS applied by different 
laboratories on both the same IHC slides and slides stained in house. 
Although manual counting of Ki67 PIs is a laborious and time-
consuming task, feasibility studies examining the time and cost for 
implementing and performing VDS are needed. At the moment it 
would require additional laboratory steps but with the advent of 
digital pathology platforms this complexity might be reduced. 
 
Especially relevant for DIA, there still do not exist a clear definition 
of an (Ki67) IHC-positive nuclei. This is imperative for development 
of DIA systems and may require international consensus definitions 
developed by pathologist and technologists. Possibly comparative 
studies could examine prognostic and predictive values of DIA with 
different definitions of positivity. 
 
At the moment, artificial intelligence is gaining momentum in many 
scientific fields including DIA. It has been shown many times that 
well-trained machine learning algorithms can identify tumour tissue 
in hematoxylin stained slides. This new technique could potentially 
make VDS obsolete, since tumour identification can be obtained on 
the Ki67 stained slide. However, until this that been validated VDS 
could also serve as an unsupervised tool for identification of tumour 
tissue for training of machine learning algorithms. 
 
The large impact of Ki67 primary Ab clone, format and stainer 
platform indicates that the source of variations should be explored 
further. Large studies comparing the effects of these parameters on 
predictive value of Ki67 and comparison to gene expression assays 
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should be completed as soon as possible, since the lack of 
standardization in this field hinders comparison of results from 
studies using different methodology. 
 
Our cell line approach to monitor IHC performance should be 
validated in a larger study. One possible study could be to include 
cell lines on all Ki67 slides in diagnostic laboratory alongside several 
cores of breast carcinoma and assess the H-scores using DIA. 
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